Clinical Trial Update: Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing immunogenicity, safety of a third BBIBP-CorV dose, and immune persistence in people living with HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BBIBP-CorV

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19, HIV Infections | Phase 4 | Status: UNKNOWN